Indivior Pharmaceuticals, Inc. (INDV): Gross Profit

Annual figures by period end, from SEC filings.

$994.00M

Year ended 2025-12-31

$1.09B

Trailing 12 months to 2026-06-30

+9.9%

3-year compound annual growth

2022-12-31 Gross Profit (USD) 2025-12-31

Period ended	Gross Profit	Change YoY	Source filing
2025-12-31	$994.00M	+3.9%	2026-02-26, From 2025-01-01
2024-12-31	$957.00M	+4.1%	2026-02-26, From 2024-01-01
2023-12-31	$919.00M	+22.7%	2026-02-26, From 2023-01-01
2022-12-31	$749.00M	n/a	2025-03-03, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
Indivior Pharmaceuticals, Inc. (INDV)	2025-12-31	$994.00M	+3.9%
Prestige Consumer Healthcare Inc. (PBH)	2026-03-31	$595.58M	-6.1%
Acadia Pharmaceuticals Inc (ACAD)	2025-12-31	$982.51M	+12.2%
Alkermes plc. (ALKS)	2025-12-31	$1.28B	-2.5%
Phibro Animal Health Corp (PAHC)	2026-06-30	$512.51M	+28.1%
Harmony Biosciences Holdings, Inc. (HRMY)	2025-12-31	$670.11M	+20.1%
Collegium Pharmaceutical, Inc (COLL)	2025-12-31	$463.26M	+22.8%
Emergent BioSolutions Inc. (EBS)	2025-12-31	$416.70M	+15.0%
Pacira BioSciences, Inc. (PCRX)	2025-12-31	$576.66M	+8.7%

Compare INDV, PBH, ACAD, ALKS side by side · Screen every company in Pharmaceutical Preparations ↗